CorMedix Prices $85 Mln Public Offering Of Common Stock

June 27, 2025 — 12:30 pm EDT

Written by RTTNews.com for RTTNews

(RTTNews) - CorMedix Inc. (CRMD) announced Friday the pricing of its public offering of 6,604,507 shares of common stock, expected to generate gross proceeds of approximately $85 million.

The offering includes a 30-day option granted to underwriters to purchase up to an additional 15 percent of the shares offered.

The offering is expected to close on or about June 30, 2025, subject to customary closing conditions.

CorMedix plans to use the net proceeds for general corporate purposes, including working capital, R&D expenses, and potential strategic transactions such as acquisitions or partnerships.

CorMedix is focused on commercializing DefenCath, its FDA-approved catheter lock solution, and expanding into additional indications including pediatric and TPN patient populations.

Currently, CRMD is trading at $12.45, down by 16.95 percent on the Nasdaq.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

CorMedix Prices $85 Mln Public Offering Of Common Stock

Tags

Latest Articles